lutetium has been researched along with Disease Models, Animal in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, RM; Breckpot, K; Ceuppens, H; D'Huyvetter, M; De Beck, L; de Mey, W; De Ridder, K; De Vlaeminck, Y; Devoogdt, N; Ertveldt, T; Goyvaerts, C; Keyaerts, M; Krasniqi, A; Lecocq, Q; Locy, H | 1 |
| Endo, K; Hanaoka, H; Hashimoto, K; Ishioka, NS; Matsumoto, S; Sakashita, T; Watanabe, S | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Nava-Cabrera, M; Oros-Pantoja, R | 1 |
| Anderson, CJ; Berkman, CE; Beyer, SK; Choy, CJ; Geruntho, JJ; Langton-Webster, B; Latoche, JD; Ling, X | 1 |
| Dahle, J; Eiríksdóttir, B; Larsen, RH; Malenge, MM; O'Shea, A; Repetto-Llamazares, AHV; Stokke, T | 1 |
| Béhé, M; Cohrs, S; Grünberg, J; Lindenblatt, D; Pellegrini, G; Schibli, R; Spycher, PR; Terraneo, N; Vukovic, D | 1 |
| Batra, SK; Fan, W; Garrison, JC; Lele, SM; Rachagani, S; Zhang, W; Zhou, Z | 1 |
| Elgström, E; Eriksson, SE; Nilsson, R; Ohlsson, T; Örbom, A; Strand, SE; Tennvall, J | 1 |
| Balkin, ER; Jia, F; Lewis, MR; Liu, D; Miller, WH; Ruthengael, VC; Shaffer, SM | 1 |
| Bäck, T; Elgström, E; Eriksson, SE; Jensen, H; Lindegren, S; Nilsson, R; Ohlsson, T; Tennvall, J | 1 |
| Dahle, J; Didierlaurent, D; Fleten, KG; Larsen, RH; Patzke, S; Pichard, A; Pouget, JP; Repetto-Llamazares, AH | 1 |
| Dadachova, E; Fisher, DR; Goldberg, GL; Jiang, Z; Phaeton, R; Revskaya, E | 1 |
| Dayton, PA; Huang, L; Rojas, JD; Satterlee, AB | 1 |
| Aarts, F; Bleichrodt, RP; Boerman, OC; de Man, B; Hendriks, T; Lomme, R | 1 |
| Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C | 1 |
| Bleichrodt, R; Boerman, O; de Jong, G; Franssen, G; Hendriks, T; Oyen, W | 1 |
| Dorn, HC; Fatouros, PP; Fuller, CE; Shultz, MD; Wilson, JD; Zhang, J | 1 |
| Eriksson, SE; Nilsson, R; Ohlsson, T; Tennvall, J | 1 |
| Baek, HS; Choi, SJ; Choi, SM; Hong, YD; Kim, JJ; Lim, JC | 1 |
| Bernard, BF; Breeman, WA; Capello, A; de Jong, M; Krenning, EP; Mearadji, A; van Eijck, CH | 1 |
| Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabahajosula, S | 1 |
| Daly, T; Descalle, MA; Fisher, D; Hartmann-Siantar, C; Hoffman, T; Lehmann, J; Lewis, MR; Miller, WH; Situ, PD; Smith, J; Volkert, WA | 1 |
| Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z | 1 |
| Miao, Y; Quinn, TP; Shelton, T | 1 |
| Aarts, F; Bleichrodt, RP; Boerman, OC; Hendriks, T; Koppe, MJ; Oyen, WJ | 1 |
| Brechbiel, MW; Buchsbaum, DJ; Chappell, LL; Khazaeli, MB; Mayo, MS; Rogers, BE | 1 |
| Blumenkranz, MS; Kessel, D; Miller, R; Qing, F; Verdooner, S; Woodburn, KW | 1 |
1 review(s) available for lutetium and Disease Models, Animal
| Article | Year |
|---|---|
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, Surface; Clinical Trials, Phase I as Topic; Cytotoxins; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Extracellular Space; Fluorescent Antibody Technique; Glutamate Carboxypeptidase II; Humans; Immunoglobulin G; Lutetium; Male; Mice; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Treatment Outcome; Yttrium Radioisotopes | 2003 |
26 other study(ies) available for lutetium and Disease Models, Animal
| Article | Year |
|---|---|
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Topics: Animals; Antigens, CD20; Cell Line, Tumor; Disease Models, Animal; Lutetium; Melanoma, Experimental; Mice; Ovalbumin; Radioisotopes; Single-Domain Antibodies | 2022 |
Comparative evaluation of radionuclide therapy using
Topics: Animals; Disease Models, Animal; Lutetium; Mice; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Tissue Distribution | 2023 |
Comparison between
Topics: Actinium; Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lutetium; Mice, Nude; Neoplasm Metastasis; Radioisotopes; Radiometry | 2021 |
Topics: Albumins; Amides; Animals; Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Glutamate Carboxypeptidase II; Heterografts; Humans; Lutetium; Male; Mice; Mice, Nude; Phosphoric Acids; Prostatic Neoplasms; Radioisotopes; Treatment Outcome | 2017 |
Combination of
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Immunoconjugates; Immunophenotyping; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, Nude; Mice, SCID; Radioisotopes; Rituximab; Xenograft Model Antitumor Assays | 2018 |
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Breaks, Double-Stranded; Female; Humans; Immunoconjugates; Lutetium; Mice; Neural Cell Adhesion Molecule L1; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrimidinones; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays | 2018 |
Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy.
Topics: Animals; Antineoplastic Agents; Autoradiography; Disease Models, Animal; Female; Hypoxia; Lutetium; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution | 2019 |
The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Topics: Animals; Antibodies, Monoclonal; Colonic Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Isotope Labeling; Lewis Blood Group Antigens; Lutetium; Male; Neovascularization, Pathologic; Radiation Dosage; Radioisotopes; Rats; Time Factors | 2013 |
Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Genes, bcl-2; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lutetium; Lymphoma, B-Cell; Mice; Oligoribonucleotides, Antisense; Peptide Nucleic Acids; Peptides, Cyclic; Proto-Oncogene Mas; Radioisotopes; Radiometry; Tissue Distribution | 2014 |
Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Astatine; Colonic Neoplasms; Disease Models, Animal; Humans; Lutetium; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rats | 2014 |
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Topics: Animals; Antibodies; Antigen-Antibody Reactions; Antigens, Neoplasm; Beta Particles; Cell Line, Tumor; Disease Models, Animal; Humans; Immunoconjugates; Iodine Radioisotopes; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, Nude; Radioisotopes; Radiopharmaceuticals; Rituximab; Tetraspanins; Tissue Distribution; Transplantation, Heterologous | 2015 |
Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
Topics: Animals; Beta Particles; Cell Line, Tumor; Disease Models, Animal; DNA Damage; Female; Humans; Immunoconjugates; Lutetium; Mice; Papillomavirus Infections; Radioimmunotherapy; Radioisotopes; Rhenium; Tissue Distribution; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combination; Lutetium; Mice; Nanoparticles; Neoplasms; Radioisotopes; Stilbenes; Treatment Outcome | 2017 |
The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
Topics: Abdominal Wall; Anastomosis, Surgical; Animals; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Combined Modality Therapy; Disease Models, Animal; Gelatinases; Hydroxyproline; Hyperthermia, Induced; Injections, Intraperitoneal; Intestines; Lutetium; Male; Mitomycin; Peritoneal Neoplasms; Radioimmunotherapy; Rats; Rats, Inbred Strains; Survival Rate; Treatment Outcome; Wound Healing | 2008 |
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Blood Cell Count; Cell Line, Tumor; Disease Models, Animal; Drug Stability; Female; Humans; Immunoconjugates; Lutetium; Mice; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Stomach Neoplasms; Time Factors | 2011 |
Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Catheter Ablation; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Fluorodeoxyglucose F18; Liver Neoplasms; Lutetium; Male; Octreotide; Positron-Emission Tomography; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rats; Reproducibility of Results; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2011 |
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
Topics: Animals; Brachytherapy; Brain Neoplasms; Coordination Complexes; Disease Models, Animal; Female; Fullerenes; Glioblastoma; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Mice, Nude; Nanotechnology; Neoplasm Transplantation; Radioisotopes; Radionuclide Imaging | 2011 |
Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
Topics: Animals; Antibodies, Monoclonal; Chelating Agents; Colonic Neoplasms; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds, 1-Ring; Immunoenzyme Techniques; Lutetium; Male; Radioimmunotherapy; Radioisotopes; Rats; Rats, Inbred BN | 2012 |
Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
Topics: alpha-MSH; Animals; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligopeptides; Radioisotopes; Radiopharmaceuticals; Receptor, Melanocortin, Type 1; Tissue Distribution | 2012 |
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Liver Neoplasms, Experimental; Lutetium; Male; Octreotide; Radioisotopes; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Survival Rate; Tumor Cells, Cultured | 2003 |
Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
Topics: Animals; Copper Radioisotopes; Disease Models, Animal; Holmium; Lutetium; Mice; Mice, Nude; Models, Statistical; Models, Theoretical; Promethium; Radioimmunotherapy; Radioisotopes; Radiometry; Radiopharmaceuticals; Rhenium; Tissue Distribution; Yttrium Radioisotopes | 2005 |
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
Topics: Animals; Antibodies, Monoclonal; Biotin; Body Weight; Brain; Chelating Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Leukocytes; Lutetium; Maximum Tolerated Dose; Platelet Count; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Yttrium Radioisotopes | 2005 |
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
Topics: alpha-MSH; Animals; Arginine; Chelating Agents; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Melanoma; Mice; Radiography; Radioisotopes; Survival Analysis | 2007 |
A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Body Weight; Colonic Neoplasms; Combined Modality Therapy; Disease Models, Animal; Hyperthermia, Induced; Infusions, Parenteral; Lutetium; Mitomycin; Neoplasms, Experimental; Peritoneal Neoplasms; Radioimmunotherapy; Rats; Rats, Inbred Strains; Survival Rate; Treatment Outcome | 2007 |
Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA).
Topics: Aniline Compounds; Animals; Chelating Agents; Colorectal Neoplasms; Cross-Linking Reagents; Disease Models, Animal; Heterocyclic Compounds; Humans; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy | 1999 |
Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy.
Topics: Animals; Choroid; Choroidal Neovascularization; Disease Models, Animal; Fluorescein; Fluorescein Angiography; Fundus Oculi; Indocyanine Green; Lutetium; Male; Metalloporphyrins; Photochemotherapy; Photosensitizing Agents; Rabbits; Retinal Neovascularization; Retinal Vessels | 2000 |